Study wrapper · #52
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Editor's note
A small uncontrolled pilot that reports dramatic results, which is exactly why it needs cautious reading. Twelve women with moderate-to-severe interstitial cystitis who had not responded to pentosan polysulfate received bladder-wall injections of BPC-157 (10 mg total) in a single procedure; 10 of 12 reported complete symptom resolution and the other 2 reported about 80% improvement, with no adverse events reported and no dropouts. But there was no placebo group, no blinding, a subjective questionnaire endpoint, and just 12 participants at a single private clinic, a design highly vulnerable to placebo effect and bias. This is a hypothesis-generating first report, not evidence of efficacy. BPC-157 is not FDA-approved for this or any indication and was removed from the FDA Category-2 compounding list; controlled trials would be needed to interpret these results.
Plain-language abstract
This small pilot study looked at BPC-157 in 12 women with interstitial cystitis, a painful bladder condition, who had not improved on the standard approved medication. Each woman received injections of BPC-157 into the bladder wall during a single procedure. Afterward, 10 of the 12 reported that their symptoms had completely gone, and the other 2 said about 80% of their symptoms had cleared. No one dropped out, and no side effects were reported. These sound like impressive results, but the study had important limitations: there was no comparison group receiving a dummy treatment, patients and doctors knew what was given, the results were based on how patients rated themselves, and only 12 people took part at one clinic. Such a design can easily overstate benefit, so this is an early observation rather than proof that the peptide helps.